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~- ]  Safety of Amlodlplne Severe Heart Failure: In 
Reduction of Sudden Death in Nondschemic Heart 
Disease 
Milton L Preesler, Peter E. Carson, Alan B. Miller, John H. Wertheimer, 
Chflstopher M. O'Connor, Gerald W. Neuberg, David J. Fdd, Robert 
N. Balkin, Anne B. Crepp for the PRAISE Investigatom. Indiana University, 
Indianapolis, IN 
Sudden cardiac death (SCD) accounts for ==50% of chronic heart failure 
(HF) deaths. The PRAISE trial suggested a potential role for amlodipine 
(Amlo) in HF but the safety and efficacy of Ca channel blockers has become 
controversial. After blinded adjudicatk, n of endpeints in 1153 patients with 
NYHA Class Ill-IV HI =, we analyzed the frequency and charectsdstics of ~cr) 
and lita-thrsatsnlng VTNF. Over a median tollow-up of 14.5 mos, 162 h~u:l 
SCD and 29 had VTNR The efficacy of Amlo vs placebo (Plac) showed a 
sign'dlcaof interaction for prespecifisd ischemfo (Isch) and non-ischemio (NI) 
almta. There were no signWcant differences among groups in NYHA dass, 
ECG parametem, usage of pacemakers or ICDs. 
Parameter Plac-lsch Amlo-lsch Plac-NI Amlo-NI 
NO, 370 ~.  212 209 
Age(F ) 684-9 69.10 624"15 594"11 
LVEF (%) 21 ~6 21 -~-5 19.6 20*6 
No. SOD 65 (17.5%) 58 (16%) 38 (18%) 21 (10%)" 
No. VI"NF 11 (3%) 9 (2.5%) 8 (4%) 1 (0.5%) 
*P = 0.05 compared to Plac 
In the Isdn stratum, there was no significant difference in SCD but in the 
NI stratum, Amlo reduced SCD by 44% (P = 0.05) and reduced combined 
$CD + VTNF by 51% (P < 0.01) as compared to Plac. The results uggest 
that patients with severe HF and ischemic heart disease may be safely 
treated with Amlo without increasing SCD. Amlo does not appear to promote 
life-threatening VT or VF and may stabilize the anttythmngenic substmto in 
non-ischemic types of heart failure. 
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~"~ The Beneficial of Llsinopdl on Effect Left Ventdcular 
Remodelling After a Rmt Myocardial Ininrction Is 
Modulated by Age. The GlSSl-3 Echo Database 
Roberto Laflni, Giantulgi NIcolosi, Aldo R Maggioni, Maria G. Frenzosi, 
$imona Badera, Serge M65son on behalf of the GISSI-3 Investigators. 
ANMCO and Istttuto 'M. Negrf, Italy 
Elderly pts am conaldemd to be at high dsk after myocardial infarction (MI). 
In GISSI-3 lisinopdl (L) started within 24 h after MI and continued for 6 weeks 
showed a larger benefit In pts > 70 y than in younger pts. We analyzed 
election fraction (EF), end.diastolic (EDVi) and end-systolic (ESVI) volume 
indexes in 2-D echo at predischerge (pD) and 6 weeks (6w) from 5101 pts 
with first MI from GISSI-3 trial. 
Pts with wall motion esynerg~t (WMA) _> 27% at pD were 32% in > 70 y, but 
only 24% in < 70 y (p < 0.001). Therefore data on EDVl changes (6w-pD) 
am presented as a functisn of age and WMA (table; mean ± SEM). 
Age WMA (%) n of pts AEOVI (mPm -2) 
L no-L 
_<70y <27 3162 -0.3=1=0.2 -0.84-0.3 
>_. 27 1012 0.5=1=0.6 1.84-0.6 
> 70y < 27 682 -0.64"0.5 0.34"0.6 
:>27 325 -1.3:1:1.2 2.44-0.9 
P-way ANOVA: 8ge x treatment, p < 0.01;WMA x treatment, p < 0.00t 
L consistently reduced EDVI enlargement in high WMA pts and this effect 
tended to be larger in pts > 70 y. Slmiler effects were found for ESVI, although 
not statistically slgnlticanL EF tended to increase overtime of about 1%, but 
the effects of L were not signirP, anL 
In conclusion, a 6w treatment with L reduced LV enlargement in lots with 
WMA _> 27% and mere so in those > 70 y of age. These findings are 
consistent with the clinical banef'~ obsen/ed in the elderly in GISSI-3 trial. 
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[ "~ Does Mode of Pacing Affect Long-Term Survival In 
the Octagenedans and Nonagenarians? 
Arshad Jahangir' Win K. Sben, S "haren A. Neubauer, Stephen C. Hammlil, 
David O. Hodge, David L Hayes. Mayo Clinic, Rochester, MN 
[mpant of pacemaker (PM) on relief of symptoms related to conduction sys- 
tem disease in the aldedy population has been well docomented. However, 
long-term sundval outcome following PM implantation i octagenerians and 
nonagenarians, particolarly with respect o mode ef pacing, has been sparsa. 
In this study, suwival of all pts (584) >_. 80 ym of age undelwent PM implan- 
tation at the Mayo Clinic from 1980-1992 was determined (KaplarvMeiar 
me~nd) Patients with chronic atrial fibdliat]on were excluded from pacing 
mode comparisons leaving 432 pts for analysis. The mean age of study 
group was 84.5 d: 3.9 yrs; the mean follow-up was 3.5 :t: 2.6 yrs. Survival 
outcomes am shown below:. 
Paring Mode Pts (n) Su~tval, % p 
lyr 3yr 5~ 
SC 310 80 57 45 0.0003 
OC 122 92 76 58 
SC: single chamber;, DC: dual chamber 
Multivariate analysis determined the following independent predictors for 
increased mortality: age (p < 0.0001), NYHA tonctional class (p _< 0.0001), 
co-meCald medical i l~as  (p _.< 0.6801), and hypeffension (p = 0.0017). 
Pacing mode, year of implant, type of conduction disease, and history of 
PAF were not independent predictors of merts]ity (p > 0.65). Selection bias 
in favor of DC pacing included: younger age (p = 0.0003), cognitively (p = 
0.0023), and physically (p = 0.013) independent pts. 
Conc/us/ons: 1) The apparent survival benefit of DC pacing is likely due to 
differences in pt selection. 2) Independent predictom for long-term smvival 
would assist us in careful evaluation and salec~on of mode of pacing in the 
very elderly. 
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( "~"~ Cardiac Surgery in the Elderly: Analysis of Outcome 
in Patients With Mltral Regurgitation 
Maufise E. Sareno, Robert L. Frye, Hartzall V. Schalf, Thomas A. Orszulak, 
A. Jamil Tajtk. Mayo Clinic, Rochester, MN 
Cardiac surgery in the elderly is considered as canying a high risk and, 
therefore, is often limited to patients with refractop/heart failure. The outcome 
of surgical conection of mitral regurgitation was analyzed in 824 patients 
operated between 1980 and 1991, 327 < 65 yesm, and 497 > 65 years 
(167 > 75 years). Patients >_. 65 years compared to those < 65 years had 
mere often ischemlc mitral reguq]ita~n (25% vs 18%, p = 0.017), class 
Ill-IV symptoms (69% vs 53%, p < 0.0001), coronary disease (54% vs 33%, 
p < 0.0001), and associated coronary surgery (46% vs 29%, p < 0.0001). 
However, they had similar ejection fraction (57 :E 13% vs 59 4- 13%, p = 
0.13) and valve repair was equally feasible (55% vs 57%, p = 0.62). Although 
oper'ath~ mortal//y was higher (11.3% vs 4.9%, p = 0.001) in the elderly 
patients, it improved In all subgroups throughout the study period: 
Age Study Padod 
1980-83 1984-87 1988-81 
< 65 0.8% 4.6% 3.6% 
>_ 65, < 75 21% 6.6% 9.8% 
>_ 75 29% 17.2% 7 .'P/= 
Feasibility of va/ve repNr Intpmvod similarly in all three age groups (p < 
0.6801) to > 70% in the 1988-1991 period. 
Postoperaf/ve surv~a/was worse In the eldedy patients (et 10 years 40 :E 
3.5% vs 68 -I- 3,4%, p '= 0.0001) but, observed to expected survival ratios 
were simgar in pattasts < 65, 65 to 75 years (p = 0.13) ar¢l >_ 75 yearn (p = 
0.10). 
We cenctude that cardiac surgery for mitr~ regurgitation i the elderly can 
be accom~ished 1)with a high properUon of va~e repair, 2) with a higher 
dsk than in younger patients but with ma~ed recent improvement, 3) with 
obsanmd to expected survival ratios similar in all age groups and, themtore, 
4) is a reasonable option when carefully ludgnd in each individual elderly 
pa~ent. 
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